الرئيسية
استكشاف
nav.journalClub
الرائج
المزيد
synapse
⌘+K
اللغة
العربية
March 3, 2026
Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation
SZ
Sanja Zepcan
Loyola University Medical Center
MK
Moujtaba Y. Kasmani
Loyola University Medical Center
RP
Rachel Pionke
See all
Key Points
Letermovir shows improved efficacy in preventing cytomegalovirus infection post-transplantation.
In this study, lettermovir treatment reduced CMV reactivation rates by 30% compared to high-dose valacyclovir.
Analysis of allogeneic hematopoietic stem cell transplant patients indicates significant differences in medication outcomes.
Understanding these treatment differences highlights the need for tailored prophylactic strategies.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Zepcan et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76085c6e9836116a2d57d
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.831
Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation | Synapse